胡曉勛++劉季萍++付書彩
[摘要] 目的 探討常規(guī)藥物和舌下免疫治療變應(yīng)性鼻炎的療效。 方法 選取我院2013年6月~2014年6月收治的變應(yīng)性鼻炎患者60例,依據(jù)治療方法將這些患者分為個體化規(guī)范化的舌下免疫治療組(n=30)和常規(guī)藥物治療組(n=30)兩組,對兩組患者的臨床癥狀評分、臨床療效、不良反應(yīng)發(fā)生情況進行統(tǒng)計分析。結(jié)果 舌下免疫治療組患者的鼻塞、鼻涕、鼻癢、噴嚏評分及總分均顯著低于常規(guī)治療組(P<0.05),治療總有效率[86.7%(26/30)]顯著高于常規(guī)藥物治療組[43.3%(13/30)](P<0.05),但兩組患者不良反應(yīng)發(fā)生率之間差異不顯著[10.0%(3/30)、6.7%(2/30),P>0.05]。 結(jié)論 變應(yīng)性鼻炎的個體化規(guī)范化的舌下免疫治療效果較常規(guī)藥物治療好,值得在臨床推廣使用。
[關(guān)鍵詞] 變應(yīng)性鼻炎;個體化規(guī)范化的舌下免疫治療;臨床癥狀;不良反應(yīng)
[中圖分類號] R765.21 [文獻標(biāo)識碼] B [文章編號] 1673-9701(2016)35-0062-03
Analysis of therapeutic effect of conventional drugs and sublingual immunotherapy on allergic rhinitis
HU Xiaoxun LIU Jiping FU Shucai
Department of ENT, Jiujiang University Affiliated Hospital, Jiujiang 332000, China
[Abstract] Objective To compare the efficacy of conventional drugs and sublingual immunotherapy on allergic rhinitis. Methods A total of 60 patients with allergic rhinitis from June 2013 to June 2014 in our hospital were enrolled and divided into individualized and standardized sublingual immunotherapy group(n=30), conventional drug treatment group(n=30) according to the treatment method. The clinical symptom score, clinical efficacy and adverse events in the two groups were statistically analyzed. Results The scores of nasal congestion, nasal discharge, nasal itching, sneezing and the total score of these above in sublingual immunotherapy group were significantly lower than those of routine treatment group(P<0.05). The total effective rate was 86.7%(26/30), which was significantly higher than that of the conventional drug treatment group(43.3%, 13/30)(P<0.05). However, there was no significant difference between the two groups in the incidence of adverse reactions[(10.0%, 3/30), 6.7% (2/30) (P>0.05)]. Conclusion Individualized normalized sublingual immunotherapy of allergic rhinitis is more effective than conventional drug therapy and worthy of clinical application.
[Key words] Allergic rhinitis; Individualized standardized sublingual immunotherapy; Clinical symptoms; Adverse reactions
變應(yīng)性鼻炎屬于一種耳鼻咽喉科疾病,在臨床極為常見,相關(guān)醫(yī)學(xué)研究表明[1],其達(dá)到了10%~25%的平均發(fā)病率。塵螨是變應(yīng)性鼻炎的主要致敏原[2]?,F(xiàn)階段,藥物治療、特異性免疫治療是臨床治療該病過程中常用的方法[3],其中臨床普遍認(rèn)為[4],特異性免疫治療是唯一的有效對因治療方法,其對變應(yīng)性疾病自然進程改變途徑為通過免疫調(diào)節(jié)機制。本研究比較了變應(yīng)性鼻炎個體化規(guī)范化舌下免疫治療與常規(guī)藥物治療的效果,發(fā)現(xiàn)前者較后者具有顯著優(yōu)勢,現(xiàn)報道如下。
1 資料與方法
1.1 一般資料
選取我院2013年6月~2014年6月收治的變應(yīng)性鼻炎患者60例,納入標(biāo)準(zhǔn):所有患者均符合變應(yīng)性鼻炎的診斷標(biāo)準(zhǔn)[5],均具有正常的肺功能,均知情同意。排除標(biāo)準(zhǔn):將有其他變應(yīng)原疾病史、近6個月內(nèi)有哮喘發(fā)作史等患者排除在外。依據(jù)治療方法將所有患者分為個體化規(guī)范化的舌下免疫治療組(舌下免疫治療組,n=30)和常規(guī)藥物治療組(n=30)。舌下免疫治療組患者中男16例,女14例,年齡5~59歲,平均(21.2±3.6)歲;病程1~36年,平均(4.6±1.2)年。常規(guī)藥物治療組患者中男15例,女15例,年齡6~59歲,平均(22.3±3.4)歲;病程2~36年,平均(4.9±1.6)年。兩組患者的一般資料比較差異均不顯著(P>0.05),具有可比性。